Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIKIDS: Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
NCT03485677Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of eliglustat in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by Sanofi. Started Apr 2018; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on NCT03485677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485677.